Chronic Lymphocytic Leukemia

Previously Treated

Age > 18

HEM0055
Phase I First in Human Study of ABBV-623 and ABBV-992 in Subjects with B-Cell Malignancies
PI: Coutre
Sponsor: AbbVie

Previously Untreated

Age ≥ 70

ECOG-ACRIN-S1925
Phase III Early Venetoclax +Obinutuzumab vs Delayed Venetoclax +Obinutuzumab in Newly Dx HR CLL/SLI
PI: Coutre
Sponsor: SWOG

SWOG-A041702
Phase III Ibrutinib Plus Obinutuzumab vs Ibrutinib Plus Venetoclax & Obinutuzumab in CLL
PI: Coutre
Sponsor: SWOG

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold